Urethroplasty for Anterior Urethral Stricture in Men With Non‐Muscle‐Invasive Bladder Cancer: Feasibility and Durability of a Pragmatic Recurrence‐Free Interval‐Oriented Strategy
International Journal of Urology · 2026-11 · 33 (11)
DOI: 10.1111/iju.70711 ↗Abstract
ABSTRACT Objectives To report the outcomes of urethroplasty in men with anterior urethral stricture and concomitant non‐muscle‐invasive bladder cancer, scheduled at least 2 years after the most recent transurethral resection. Methods We retrospectively reviewed 33 men who underwent urethroplasty for anterior urethral stricture with a history of transurethral resection for non‐muscle‐invasive bladder cancer. Those wishing to undergo anastomotic or substitution urethroplasty waited until 2 years had elapsed since the most recent resection, with intervention limited to symptom‐driven dilation. Others with a stricture confined to the distal anterior urethra were offered ventral meatotomy or perineal urethrostomy without delay. Success was defined as passage of a flexible cystoscope through the reconstructed segment without further intervention. Results Median stricture length was 15 mm. Anastomotic urethroplasty was performed in 12, dorsal onlay augmentation urethroplasty in 7, perineal urethrostomy in 8, staged urethroplasty in 3, and ventral meatotomy in 3, at a median of 34 months after resection. The seven patients who waited showed no worsening of the stricture. At a median follow‐up of 58 months, 28 (84.8%) remained free of re‐stricture, stricture‐free survival at 5 years was 82.0%, and no re‐stricture was symptomatic. Flow rate, residual volume, and patient‐reported outcomes improved. Bladder tumor recurred in three, in whom repeat resection was accomplished through the reconstructed urethra without dilation. Conclusions Urethroplasty scheduled as an institutional approach, not a validated recommendation, at least 2 years after the most recent resection was feasible, provided durable patency, and preserved endoscopic access for bladder cancer management; this interval requires validation in larger cohorts.
EUVIMED